Linipon-S (Risperidone)

Risperidone works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors in the brain. This dual antagonism reduces dopaminergic overactivity linked to psychosis and balances serotonergic pathways that influence mood, resulting in improvement of psychiatric symptoms.

The appropriate dose of Linipon‑S is determined by the prescribing clinician based on the patient’s condition, age, response, and tolerability. Dosage may be adjusted during treatment, and patients should follow the specific instructions provided by their healthcare professional.

Risperidone is classified as pregnancy category B1, indicating that animal studies have not shown risk but there are limited human data. It should be used only if the potential benefit justifies any possible risk to the fetus. Breastfeeding mothers should discuss risks with their doctor, as the drug can pass into milk.

To place an order, submit an enquiry on the Linipon‑S product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Compared with typical antipsychotics such as haloperidol, risperidone (Linipon‑S) offers a broader receptor profile, targeting both dopamine and serotonin receptors, which often results in fewer extrapyramidal side effects. However, it may cause metabolic changes and prolactin elevation, so the choice depends on individual patient factors and clinician judgment.

Linipon‑S should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or direct sunlight.

Linipon‑S is administered orally, typically as a tablet or capsule taken with or without food as directed by a healthcare professional. The exact form and dosing schedule should be followed according to the prescriber’s instructions.

Serious risks include neuroleptic malignant syndrome, a potentially fatal reaction characterized by fever, muscle rigidity, and autonomic instability; tardive dyskinesia, which involves persistent involuntary movements; severe hypotension; seizures; and agranulocytosis, a dangerous drop in white blood cells. Patients should be monitored closely for these events.

Linipon‑S is contraindicated in patients with known hypersensitivity to risperidone or any of its excipients. It should be used with caution, or avoided, in individuals with severe cardiovascular disease, uncontrolled diabetes, significant hepatic or renal impairment, and in elderly patients with dementia-related psychosis due to an increased risk of mortality.